Hebatallah Emam Mohammed Ahmed Attallah

Dr. Hebatallah Emam Mohammed Ahmed Attallah


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2023 in Biology
Verified
Journal Article
Open access
PDF file
MSMohamed Soltan
Mohamed Soltan
DEDr. Muhammad Alaa Eldeen
Dr. Muhammad Alaa Eldeen
Bayan SajerBayan Sajer
Bayan Sajer
RAReda F. A. Abdelhameed
Reda F. A. Abdelhameed
FAfawziah Abdulrazaq M Alsalmi
fawziah Abdulrazaq M Alsalmi
Khaled DarwishKhaled Darwish
Khaled Darwish
Epithelial cell transforming 2 (ECT2) is a potential oncogene and a number of recent studies have correlated it with the progression of several human cancers. Despite this elevated attention for ECT2 in oncology-related reports, there is no collective study to combine and integrate the expression and oncogenic behavior of ECT2 in a panel of human cancers. The current study started with a differential expression analysis of ECT2 in cancerous versus normal tissue. Following that, the study asked for the correlation between ECT2 upregulation and tumor stage, grade, and metastasis, along with its effect on patient survival. Moreover, the methylation and phosphorylation status of ECT2 in tumor versus normal tissue was assessed, in addition to the investigation of the ECT2 effect on the immune cell infiltration in the tumor microenvironment. The current study revealed that ECT2 was upregulated as mRNA and protein levels in a list of human tumors, a feature that allowed for the increased filtration of myeloid-derived suppressor cells (MDSC) and decreased the level of natural killer T (NKT) cells, which ultimately led to a poor prognosis survival. Lastly, we screened for several drugs that could inhibit ECT2 and act as antitumor agents. Collectively, this study nominated ECT2 as a prognostic and immunological biomarker, with reported inhibitors that represent potential antitumor drugs.

2 May 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
MZMohamed Samir Ahmed Zaki
Mohamed Samir Ahmed Zaki
DEDr. Muhammad Alaa Eldeen
Dr. Muhammad Alaa Eldeen
WAWaleed K. Abdulsahib
Waleed K. Abdulsahib
ASAyed Shati
Ayed Shati
YAYoussef Al-qahtani
Youssef Al-qahtani
RERefaat Eid
Refaat Eid
Emerging research findings have shown that a centrosomal protein (CEP55) is a potential oncogene in numerous human malignancies. Nevertheless, no pan-cancer analysis has been conducted to investigate the various aspects and behavior of this oncogene in different human cancerous tissues. Numerous databases were investigated to conduct a detailed analysis of CEP55. Initially, we evaluated the expression of CEP55 in several types of cancers and attempted to find the correlation between that and the stage of the examined malignancies. Then, we conducted a survival analysis to determine the relationship between CEP55 overexpression in malignancies and the patient’s survival. Furthermore, we examined the genetic alteration forms and the methylation status of this oncogene. Additionally, the interference of CEP55 expression with immune cell infiltration, the response to various chemotherapeutic agents, and the putative molecular mechanism of CEP55 in tumorigenesis were investigated. The current study found that CEP55 was upregulated in cancerous tissues versus normal controls where this upregulation was correlated with a poor prognosis in multiple forms of human cancers. Additionally, it influenced the level of different immune cell infiltration and several chemokines levels in the tumor microenvironment in addition to the response to several antitumor drugs. Herein, we provide an in-depth understanding of the oncogenic activities of CEP55, identifying it as a possible predictive marker as well as a specific target for developing anticancer therapies.

1 February 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
RERefaat Eid
Refaat Eid
DEDr. Muhammad Alaa Eldeen
Dr. Muhammad Alaa Eldeen
MSMohamed Soltan
Mohamed Soltan
MAMubarak Al-Shraim
Mubarak Al-Shraim
MZMohamed Samir Ahmed Zaki
Mohamed Samir Ahmed Zaki
HHHesham Sayed Hassan
Hesham Sayed Hassan
Background: Bisphenol A (BPA) is an environmental contaminant that can induce deleterious organ effects. Human Cytochrome P450 CYP2C9 enzyme belongs to the essential xenobiotic-metabolizing enzymes, producing ROS as a byproduct. Astaxanthin (ATX) is a powerful antioxidant that protects organs and tissues from the damaging effects of oxidative stress caused by various diseases. Aim of the study: This study investigated the possible protective impacts of ATX against BPA-induced nephrotoxicity and its underlying mechanism. Materials and methods: Kidney tissues were isolated and examined microscopically from control, protected, and unprotected groups of rats to examine the potential protective effect of ATX against nephrotoxicity. Moreover, a molecular dynamic (MD) simulation was conducted to predict the performance of ATX upon binding to the active site of P450 CYP2C9 protein receptor as a potential mechanism of ATX protective effect. Results: Implemented computational methods revealed the possible underlying mechanism of ATX protection; the protective impact of ATX is mediated by inhibiting P450 CYP2C9 through binding to its dimeric state where the RMSF value for apo-protein and ATX-complex system were 5.720.57 and 1.040.41, respectively, implicating the ATX-complex system to have lesser variance in its residues, leading to the prevention of ROS excess production, maintaining the oxidant-antioxidant balance and re-establishing the proper mitochondrial functionality. Furthermore, the experimental methods validated in silico outcomes and revealed that ATX therapy effectively restored the typical histological architecture of pathological kidney tissues. Conclusions: ATX prevents BPA-induced nephrotoxicity by controlling oxidative imbalance and reversing mitochondrial dysfunction. These outcomes shed new light on the appropriate use of ATX as a treatment or prophylactic agent for these severe conditions.

23 June 2026 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DEDr. Muhammad Alaa Eldeen
Dr. Muhammad Alaa Eldeen
ARAhmed Mohamed Refaat
Ahmed Mohamed Refaat
HAHebatallah Emam Mohammed Ahmed Attallah
Hebatallah Emam Mohammed Ahmed Attallah
HHHesham Sayed Hassan
Hesham Sayed Hassan
MAMohammed Abdullah Alshehri
Mohammed Abdullah Alshehri
Bonglee KimBonglee Kim
Bonglee Kim
RNA metabolism regulators remain insufficiently characterized across tumor types, despite the substantial expansion of multi-omics datasets. LSM12, a membe